欧美成人精品三级网站,肥白大屁股bbwbbwhd,国产剧情国产精品一区,精品无人乱码高清在线观看

Wuxi Gotele Metal Products Co., Ltd : CN EN
Home >>News >>News of Medical Acessories

Chinese Cell Therapy Effective in Small Multiple Myelome Trial

Recently, China’s Nanjing Legend Biotech Co. conducted a trial testing the effectiveness of an experimental therapy to treat multiple myeloma. Multiple myeloma is a rate form of blood plasma cancer. The trial proved successful, meaning it induced remission in most patients including those with advanced multiple myelmoa. The trial uses a new drug that utilizes CAR-T therapies, a relatively new medical innovation. 


How It Works

The study run and developed by Nanjing Legend Biotech Co. tested a chimeric antigen receptor T-cell (CAR-T) therapy thirty-five patients. Of the thirty-five nineteen were used in the trial.  Of the nine-teen patients, fourteen reached complete remission after fourth months. The American Society of Clinical Oncology featured the data at their annual meeting. The drug candidate used is known as LCAR-B38M. It is designed to target a protien called BCMA, which is found on cancerous blood plasma cells. CAR-T therapies require a difficult process. It first requires the extraction of immune system T cells from the patient, then their DNA is altered to sharpen their ability to spot and kill cancer cells, lastly the altered cells are infused back into the same patient. Using this technology not only treats the cancer, it offers the possibility for long term remission.  However, there were some negative side effects that came with many patients in the trial. Nearly 85% of patients temporarily developed cytokine release syndrome (CRS). CRS is a potoentially life-threatening inflammatory condition, but the condition was only temporary and easily managed using anti-inflammatory medications.

Continued Use

Due to the positive response experienced by so many in the small trial, China’s Nanjing Legend Biotech Co. hopes to enroll 100 new patients into the trial . They also desire to find other collaborators in the US to conduct a smilar trial in the United States starting as early as 2018.  As of now, two US companies have filed for FDA approval to use CAR-T drugs designed to target different protiens. The FDA will make its decision to approve or dissapprove of these therapies by November 29,2017. If approved CAR-T therapies can be used to treat and induce remission in advanced non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. These advances in medical innovations are putting us one step closer to curing hundreds of diseases and illnesses plaguing millions of people around the world.


HomeTelProductsContact
CN EN
主站蜘蛛池模板: 午夜精品久久久久久久| 一本色综合网久久| 日韩精品一区二区三区中文| 亚洲国产初高中女| 亚洲国产精品久久网午夜| 色欲天天婬色婬香综合网| 96国产xxxx免费视频| 亚洲国产av无码精品无广告| 男男车车的车车网站w98免费| 国产欧美视频综合二区| 成年男女免费视频网站| 国产免费午夜福利蜜芽无码| 狼人视频国产在线视频www色| 国产成人愉拍精品| 日本一道高清一区二区三区 | 国产成人综合色就色综合 | 日本一区二区在线播放| 亚洲国产超清无码专区| 中国亚州女人69内射少妇| 亚洲一二区制服无码中字| 春药玩弄少妇高潮吼叫| 欧美成人一区二区三区片免费| 久久综合精品国产一区二区三区无| 秋霞鲁丝无码一区二区三区| 四虎永久在线精品8848a| 不卡无码人妻一区三区| 日韩精品人妻中文字幕有码 | 免费观看全黄做爰的视频| 99精品久久久中文字幕| 男女免费观看做爰视频在线观看| 国产精品国产三级国产an| 精品人妻无码专区在线无广告视频| 少妇人妻久久无码专区| 国产欧美日韩中文久久| 中文字幕欧洲有码无码| 中国女人做爰视频| 野外做受又硬又粗又大视频√| 亚洲aⅴ天堂av天堂无码app| 尤物蜜芽国产成人精品区| 人与嘼交av免费| 国产欧美成人一区二区a片|